» Articles » PMID: 11079531

Delayed Recovery of Movement-related Cortical Function in Parkinson's Disease After Striatal Dopaminergic Grafts

Overview
Journal Ann Neurol
Specialty Neurology
Date 2000 Nov 18
PMID 11079531
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Intrastriatal transplantation of dopaminergic neurones aims to repair the selective loss of nigrostriatal projections and the consequent dysfunction of striatocortical circuitries in Parkinson's disease (PD). Here, we have studied the effects of bilateral human embryonic dopaminergic grafts on the movement-related activation of frontal cortical areas in 4 PD patients using H2 15O positron emission tomography and a joystick movement task. At 6.5 months after transplantation, mean striatal dopamine storage capacity as measured by 18F-dopa positron emission tomography was already significantly elevated in these patients. This was associated with a modest clinical improvement on the Unified Parkinson's Disease Rating Scale, whereas the impaired cortical activation was unchanged. At 18 months after surgery, there was further significant clinical improvement in the absence of any additional increase in striatal 18F-dopa uptake. Rostral supplementary motor and dorsal prefrontal cortical activation during performance of joystick movements had significantly improved, however. Our data suggest that the function of the graft goes beyond that of a simple dopamine delivery system and that functional integration of the grafted neurones within the host brain is necessary to produce substantial clinical recovery in PD.

Citing Articles

Revealing induced pluripotent stem cells' potential as a better alternative to embryonic stem cells for Parkinson's disease treatment based on single-cell RNA-seq.

Zhang S, Jiang X, Yan M, Cheng Z, Bi J, Wang Q Braz J Med Biol Res. 2024; 57:e13482.

PMID: 39699375 PMC: 11653487. DOI: 10.1590/1414-431X2024e13482.


Overcoming Methodological Challenges for Advancing Stem Cell Therapies in Parkinson's Disease.

Polgar S, Finkelstein D, Karimi L Cell Transplant. 2024; 33:9636897241246355.

PMID: 38634440 PMC: 11027592. DOI: 10.1177/09636897241246355.


Dopaminergic Cell Replacement for Parkinson's Disease: Addressing the Intracranial Delivery Hurdle.

Maheshwari S, Akram H, Bulstrode H, Kalia S, Morizane A, Takahashi J J Parkinsons Dis. 2024; 14(3):415-435.

PMID: 38457149 PMC: 11091588. DOI: 10.3233/JPD-230328.


Cell-therapy for Parkinson's disease: a systematic review and meta-analysis.

Wang F, Sun Z, Peng D, Gianchandani S, Le W, Boltze J J Transl Med. 2023; 21(1):601.

PMID: 37679754 PMC: 10483810. DOI: 10.1186/s12967-023-04484-x.


Human iPSC-derived midbrain organoids functionally integrate into striatum circuits and restore motor function in a mouse model of Parkinson's disease.

Zheng X, Han D, Liu W, Wang X, Pan N, Wang Y Theranostics. 2023; 13(8):2673-2692.

PMID: 37215566 PMC: 10196819. DOI: 10.7150/thno.80271.